Condicionantes de acceso a nuevos medicamentos dermatológicos en España: resultados del proyecto EQUIDAD

Sánchez Díaz, M; Flórez, Á; Ara Martín, M; Arias Santiago, S; Botella Estrada, R; Cañueto, J; Carretero Hernández, G; Coto Segura, P; de Eusebio Murillo, E; García Latasa de Araníbar, F J.
Actas dermo-sifiliogr. (Ed. impr.) ; 115(3): 237-245, Mar. 2024. mapas, tab
Artículo en Español | IBECS (España) | ID: ibc-231395

Documentos relacionados

  1. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study
  2. Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.
  3. Shortening Synthetic Routes to Small Molecule Active Pharmaceutical Ingredients Employing Biocatalytic Methods.
  4. [Defined daily doses in drugs with combinations of active principles: differences between three calculation methods.]
  5. On precision dosing of oral small molecule drugs in oncology.
  6. Predicting drug characteristics using biomedical text embedding.
  7. The current state of understanding of oncology expanded access programs in Malaysia.
  8. Age and sex differences in pharmaceutical contamination in a keystone scavenger.
  9. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
  10. Ionic Liquids: New Forms of Active Pharmaceutical Ingredients with Unique, Tunable Properties.